Brigatinib vs Crizotinib phase 3 interim results

In September 2018, Takeda reported a pre-designated first interim analysis of a phase 3 trial in the New England Journal of Medicine. The study enrolled 275 ALK inhibitor naive patients. Half got Brigatinib and half got Crizotinib.

For Brigatinib: at 12 months the PFS was 67%, objective response rate was 71%, and intracranial response rate for patients with brain lesions was 78%.

For Crizotinib: at 12 months the PFS was 43%, objective response rate was 60%, and intracranial response rate for patients with brain lesions was 29%.

For 12 month PFS the P value was less than 0.001. Which means the chance that the results are completely wrong are 0.1%

https://www.ncbi.nlm.nih.gov/pubmed/30280657

This entry was posted in Brain metastases, brigatinib-Alunbrig from Takeda, crizotinib - Xalkori from Pfizer, Lung cancer, Research. Bookmark the permalink.

Leave a Reply